Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus

Psychopharmacology
M C MedranoJoseba Pineda

Abstract

Morphine withdrawal is associated with a hyperactivity of locus coeruleus (LC) neurons by an elevated glutamate neurotransmission in this nucleus. We postulate that reductions in the amount of glutamate in the LC by enhancing its reuptake or inhibiting its release could attenuate the behavioral and cellular consequences of morphine withdrawal. We investigated the effect of chronic treatment with ceftriaxone (CFT), an excitatory amino acid transporter (EAAT2) enhancer, and acute administration of topiramate (TPM), a glutamate release inhibitor, on morphine withdrawal syndrome and withdrawal-induced glutamate receptor (GluR) desensitization in LC neurons from morphine-dependent rats. Morphine withdrawal behavior was measured after naltrexone administration in rats implanted with a morphine (200 mg kg(-1)) emulsion for 3 days. GluR desensitization in the LC was assessed by performing concentration-effect curves for glutamate by extracellular electrophysiological recordings in vitro. Treatments with CFT or TPM reduced, in a dose-related manner, the total behavioral score of naltrexone-precipitated morphine withdrawal. CFT and TPM, at doses that were effective in behavioral tests, also reduced the induction of GluR desensitization n...Continue Reading

References

May 1, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·I M Coupar
May 1, 1992·Trends in Neurosciences·G F KoobL Stinus
Jun 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A Verma, S K Kulkarni
Sep 1, 1994·Neuron·J D RothsteinR W Kuncl
Nov 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·K RasmussenG K Aghajanian
Apr 16, 1999·European Journal of Pharmacology·A Salem, W Hope
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Daniele F ZullinoJacques Besson
Mar 1, 2003·Neurochemical Research·Mikael AngehagenElisabeth Hansson
Apr 2, 2003·Brain Research. Brain Research Reviews·Craig W Berridge, Barry D Waterhouse
Mar 19, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Olga ValverdeRafael Maldonado
Apr 6, 2004·Trends in Pharmacological Sciences·Eric J Nestler
Oct 7, 2004·European Journal of Pharmacology·Yukihiro Noda, Toshitaka Nabeshima
Nov 8, 2006·British Journal of Pharmacology·P M Beart, R D O'Shea
Jun 27, 2007·British Journal of Pharmacology·S M RawlsM Amin
Apr 11, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hans G CruzChristian Lüscher
May 22, 2009·Expert Opinion on Therapeutic Targets·Lennart BunchAnders A Jensen
Mar 11, 2010·Behavioural Pharmacology·Scott M RawlsJae Kim
Jul 1, 2011·Drug and Alcohol Dependence·Adam BisagaEdward V Nunes
Sep 6, 2011·Pharmacology, Biochemistry, and Behavior·Mark J NiciuGerard Sanacora
Aug 29, 2012·Future Medicinal Chemistry·Chien-Liang Glenn LinMarcie A Glicksman
Sep 8, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Heather Trantham-DavidsonLori A Knackstedt

❮ Previous
Next ❯

Citations

Dec 16, 2016·Naunyn-Schmiedeberg's Archives of Pharmacology·Mohamed M Abdel-DaimAbdelazim Ibrahim
Dec 26, 2016·Peptides·Richard J Bodnar
Mar 26, 2016·World Journal of Psychiatry·Jennifer R Ayers-RinglerDoo-Sup Choi
Aug 9, 2019·The Journal of Pharmacology and Experimental Therapeutics·Kelly E DunnElise M Weerts
May 20, 2017·Genes, Brain, and Behavior·S M JimenezK K Szumlinski

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.